Teva Pharmaceutical Industries Ltd. $TEVA Shares Bought by Menora Mivtachim Holdings LTD.

Key Points

• Menora Mivtachim raised its stake in Teva by 1.1% in Q3 to 38,920,294 shares, representing about 3.39% of the company and roughly $786.2 million, making TEVA its fifth-largest holding.
• Corporate insiders have sold 948,499 shares (~$30.9 million) over the last 90 days, including EVP Eliyahu Sharon Kalif’s sale of 345,810 shares at an average of $33.64; insiders now own 0.49% of the stock.
• Teva topped expectations with Q4 results (EPS $0.96 vs. $0.65 est., revenue $4.71B, +11.4% YoY), set FY2026 guidance of 2.57–2.77 EPS, and several analysts have raised price targets (consensus target ~$37.67, some to $40–$42).

Menora Mivtachim Holdings LTD. raised its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 1.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,920,294 shares of the company's stock after purchasing an additional 427,000 shares during the period. Teva Pharmaceutical Industries accounts for 4.0% of Menora Mivtachim Holdings LTD.'s holdings, making the stock its 5th biggest position. Menora Mivtachim Holdings LTD. owned about 3.39% of Teva Pharmaceutical Industries worth $786,190,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Phoenix Financial Ltd. lifted its stake in Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company's stock valued at $834,164,000 after buying an additional 3,533,800 shares in the last quarter. National Pension Service increased its stake in Teva Pharmaceutical Industries by 24.2% during the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company's stock worth $41,881,000 after buying an additional 404,526 shares in the last quarter. Public Sector Pension Investment Board increased its stake in Teva Pharmaceutical Industries by 11.5% during the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company's stock worth $13,543,000 after buying an additional 69,000 shares in the last quarter. Oak Harvest Investment Services acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company's stock valued at $761,455,000 after acquiring an additional 4,306,363 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Eliyahu Sharon Kalif sold 345,810 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the sale, the executive vice president owned 57,478 shares of the company's stock, valued at approximately $1,933,559.92. The trade was a 85.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Richard Daniell sold 17,295 shares of the company's stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the completion of the transaction, the executive vice president owned 85,755 shares in the company, valued at $2,715,860.85. This represents a 16.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 948,499 shares of company stock valued at $30,897,071 over the last ninety days. Corporate insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $29.34 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The stock's fifty day moving average is $32.96 and its two-hundred day moving average is $26.55. The firm has a market capitalization of $33.73 billion, a P/E ratio of 24.45, a price-to-earnings-growth ratio of 10.20 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.65 by $0.31. The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company's revenue for the quarter was up 11.4% on a year-over-year basis. During the same period last year, the company earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on TEVA shares. Jefferies Financial Group lifted their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a "buy" rating in a research note on Tuesday, January 6th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 31st. Scotiabank upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a "sector outperform" rating in a report on Thursday, January 29th. Piper Sandler reiterated an "overweight" rating and issued a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. Finally, Truist Financial raised their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a research note on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $37.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.